Skip to main content
Story 26 November 2018
Public

Open Call: Share your vision for the future of healthcare and personal care with Evonik

events-evonik
Ana Luisa Pinho

On 5 and 6 February 2019, a selected number of highly innovative companies funded by the European Innovation Council (EIC) pilot will have the opportunity to present their business cases and ideas and to connect and network with Evonik managers in Essen, Germany.

The EIC pilot and Evonik invite you to apply for this EIC Corporate Day and present your company, discover challenges and explore business opportunities within the healthcare and personal care industries.

Evonik is one of the world’s leading specialty chemicals companies. The company is present in more than 100 countries and employs over 36,000 people. In fiscal 2017, the enterprise generated sales of around €14.4 billion and an operating profit (adjusted EBITDA) of about €2.36 billion.

Applications are open until 14 December 2018. Apply now!

Companies funded under the SME Instrument, Fast Track to Innovation and FET-Open programs are welcome to apply. The selected companies will have the chance to present their solutions and Evonik representatives. Following the presentations, participants have the opportunity to engage in one-to-one meetings, receive feedback from top corporate managers and explore joint business opportunities.

The event is open to all innovative approaches to:

•    Polymer-based medical devices

•    Tissue engineering

•    Advanced food ingredients 

•    Active ingredients and delivery systems

•    Natural-based or bio-degradable high-performance personal care products

•    Microbiome

 

This opportunity is brought to you by the EIC pilot Business Acceleration services. See more detailed information here.

Should you have any questions regarding the event or your eligibility, please refer to our helpdesk: contact@phase3-services.eu 

 

DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.

Please log in to see comments and contribute